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OBJECTIVE — This randomized, four-arm, placebo-controlled, dose-ranging phase 2 trial
was conducted to determine whether repeated subcutaneous injections of the altered peptide
ligand, NBI-6024, designed to inhibit autoreactive T-cells, improves -cell function in patients
with recently diagnosed type 1 diabetes.
RESEARCH DESIGN AND METHODS — A total of 188 patients, aged 10–35 years,
withrecentlydiagnosedtype1diabeteswererandomlyassignedforatreatmentconsistingofthe
subcutaneous administration of placebo or 1, 0.5, or 0.1 mg NBI-6024 at baseline, weeks 2 and
4, and then monthly until month 24. Fasting, peak, and area under the curve (AUC) C-peptide
concentrations during a 2-h mixed-meal tolerance test were measured at 3-month intervals
duringtreatment.Immunefunctionparameters(isletantibodiesandCD4andCD8T-cells)were
also studied.
RESULTS — The mean peak C-peptide concentration at 24 months after study entry showed
no signiﬁcant difference between the groups treated with 0.1 mg (0.59 pmol/ml), 0.5 mg (0.57
pmol/ml),and1.0mgNBI-6024(0.48pmol/ml)andtheplacebogroup(0.54pmol/ml).Fasting,
stimulated peak, and AUC C-peptide concentrations declined linearly in all groups by 60%
over the 24-month treatment period. The average daily insulin needs at month 24 were also
comparablebetweenthefourgroups.Notreatment-relatedchangesinisletantibodiesandTcell
numbers were observed.
CONCLUSIONS — Treatment with altered peptide ligand NBI-6024 at repeated doses of
0.1, 0.5, or 1.0 mg did not improve or maintain -cell function.
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T
ype 1 diabetes results from a T-cell–
mediated autoimmune attack
against the insulin-producing cells
of the pancreatic islets (1–3). There is no
curative treatment available to control
these autoreactive T-cells, rendering the
patients dependent on insulin injections
for normoglycemia. A treatment that
could stop or reduce autoimmune de-
struction of pancreatic -cells would be a
major advance in diabetes treatment and
could potentially prevent diabetes in in-
dividuals genetically predisposed to de-
veloping the disease (4).
There is potential to target speciﬁc
populations of autoreactive T-cells by
identifying the dominant antigens re-
sponsible for their activation and produc-
ing a soluble altered peptide ligand (APL)
to block or change this response. The in-
sulin B (9-23) peptide has been shown to
be an important antigen of T-cells in au-
toimmune diabetes in animals and hu-
mans (5). NBI-6024 is an APL and
contains two natural L-amino acid substi-
tutions in the (9-23) sequence of the B-
chainofinsulin.Alanineissubstitutedfor
tyrosine at position 16, which is a key
contact site at the T-cell receptor and at
position 19 for cysteine. The resulting
APL (Ala
16,19), known as NBI-6024, does
notactivateinsulinB(9-23)–reactivemu-
rine or human T-cells (6). Nonobese dia-
betic mice treated with NBI-6024 are
protected from developing diabetes, even
though other T-cells with different anti-
genic speciﬁcities were present, suggest-
ing that the immune response induced by
the APL may regulate pathogenic T-cells
through the production of regulatory cy-
tokines such as interleukin-4 (6).
Preliminary results of three studies in
adult male patients with type 1 diabetes
had indicated that NBI-6024 administra-
tion is safe and well tolerated (7,8). To
investigate the pharmacological potential
ofNBI-6024toimprove-cellfunction,a
multicenter, randomized, four-arm, pla-
cebo-controlled phase 2 trial was per-
formed. The primary objective of the trial
wastoassesstheeffectofrepeatedadmin-
istrationsofNBI-6024onendogenousin-
sulin production as measured by
C-peptide concentration in adult and ad-
olescent patients with recent-onset type 1
diabetes. Insulin usage, glycemic control,
and immune function were also assessed.
RESEARCH DESIGN AND
METHODS— Patients with recent-
onset type 1 diabetes were selected ac-
cording to the following criteria: age
10–17years(adolescentgroup)or18–35
years (adult group), symptom duration
for no longer than 6 months, treatment
with insulin for 3 months, positive re-
sult on testing for islet autoantibodies
(anti-GAD antibodies or anti-islet cell
[ICA512] antibodies or anti-insulin anti-
bodies provided that the patient had not
been receiving insulin therapy for 2
●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●
From the
1Diabetes Research Institute, Forschergruppe Diabetes e.V., Munich, Germany; the
2Diabetes
Clinical Trials Unit, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa, and
3Clinical Development, Neurocrine Biosciences, San Diego, California.
Corresponding author: Anette-G. Ziegler, anziegler@lrz.uni-muenchen.de.
Received6April2009andaccepted3August2009.Publishedaheadofprintathttp://care.diabetesjournals.
orgon18August2009.DOI:10.2337/dc09-0449.Clinicaltrialreg.no.NCT00873561,clinicaltrials.gov.
*A complete list of the NBI-6024 Study Group can be found in the APPENDIX.
© 2009 by the American Diabetes Association. Readers may use this article as long as the work is properly
cited, the use is educational and not for proﬁt, and the work is not altered. See http://creativecommons.
org/licenses/by-nc-nd/3.0/ for details.
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby
marked “advertisement” in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
Emerging Treatments and Technologies
ORIGINAL ARTICLE
2036 DIABETES CARE, VOLUME 32, NUMBER 11, NOVEMBER 2009 care.diabetesjournals.orgweeks), stimulated C-peptide peak con-
centration between 0.4 and 3.0 pmol/ml,
BMI 28 kg/m
2, laboratory and electro-
cardiogram results within normal ranges,
and compliance with insulin treatment.
Pregnant or lactating women were ex-
cluded, and female patients with child-
bearing potential had to practice an
acceptable contraceptive technique from
30 days before enrollment until 30 days
after the last dose of study drug. Written
informedconsentwasobtainedfromeach
patient. The trial was approved by the
ethics committee at each center.
Study centers
A total of 22 centers participated in the
study including six centers in South Africa
(103 patients randomized), one in the U.K.
(three patients), two in the Czech Republic
(23 patients), four in Spain (10 patients),
oneinFinland(5patients),twoinGermany
(33 patients), four in Canada (9 patients),
and two in France (2 patients).
Study design
Thetrialwasperformedasaphase2,mul-
ticenter, randomized, double-blind, pla-
cebo-controlled, parallel, dose-ranging
study between 2001 and 2006. Of 266
patients screened, a total of 188 patients
were randomly assigned, including 111
adolescents(Fig.1).Eligiblepatientswere
randomly assigned in a 1:1:1:1 ratio to
one of the following treatments: 0.1 mg
NBI-6024 (n  50), 0.5 mg NBI-6024
(n  48), 1 mg NBI-6024 (n  43), or
placebo (n  47). On day 1, patients re-
ceived their ﬁrst dose of study drug and
weredischarged2hpostdoseatthedis-
cretionoftheinvestigator.Thestudydrug
was administered subcutaneously for a
total of 26 times over a 24-month period.
The ﬁrst three doses were administered
every 2 weeks (induction phase); all sub-
sequent dosing occurred monthly (main-
tenance phase). Dose and dosing
frequency were selected after considering
immune efﬁcacy and tolerability in ani-
malstudies.Patientsreturnedtothestudy
center to receive the study drug and have
efﬁcacy and safety assessments per-
formed. Patients continued with their
normal insulin regimen throughout the
study, unless changes were clinically in-
dicated. To avoid possible confounding
through differences in glycemic control
among the groups, diabetes management
andglycemictargetswerestandardizedas
much as possible in all patients. Patients
withA1Clevels8%hadadditionalcon-
tacts with the investigator to improve
their metabolic control. All patients were
treated with intensive insulin therapy.
End point assessments
The primary efﬁcacy variable was the 2-h
peak C-peptide level at 24 months. A
mixed-meal tolerance test (Boost High
Protein from Novartis in an amount of 6
ml/kg body weight, up to 360 ml) was
administered to collect stimulated C-
peptide samples (0, 30, 60, 90, and 120
min) every 3 months and at the follow-up
visit. Secondary efﬁcacy variables were
the area under the curve (AUC0–120 min),
C-peptide at 24 months, the prescribed
insulin usage and glycemic control, as-
sessed by A1C levels, and the hypo- and
hyperglycemic events documented in the
patient’s diary. C-peptide concentrations
and A1C were measured at a central lab-
oratory (ICON Central Laboratories,
Farmingdale,NY)witharadioimmunoas-
say (Diagnostic Systems Laboratories)
and high-pressure liquid chromatogra-
phy,respectively.Thereportedinterassay
coefﬁcient of variation of the C-peptide
assay is 5.3% at a concentration of 0.55
nmol/l and the lower limit of detection is
0.03 nmol/l.
Safety parameters and hypoglycemic
events
Safety parameters included vital signs
(bodytemperature,supineheartrate,and
bloodpressure)beforeand1hafterstudy
drug administration, laboratory tests (he-
matology, clinical chemistry, and urinal-
ysis with microscopy), and quarterly
physicalexaminationsaswellasanelec-
trocardiogram and documentation of
adverse events and concomitant medi-
cation. Hypoglycemic events were de-
ﬁned as any blood glucose level 50
mg/dl (3 mmol/l) with or without typical
symptoms or typical symptoms if the
blood glucose level was 50 mg/dl. If the
patient required intervention by another
person, the event was deﬁned as a “major
hypoglycemic event.”
Immune markers
CD4 and CD8 T-cell numbers were mea-
sured by ﬂow cytometry on whole blood
using a standard protocol at a central lab-
oratory (ICON Central Laboratories,
Dublin, Ireland). Antibodies to insulin,
GAD65, and IA-2 were measured by
ICON Central Laboratories (Farming-
dale, NY) using radiobinding assays
(Kronus, Boise, ID) according to the
manufacturer’s instructions.
Statistical methods
All data are summarized by treatment
group. All randomly assigned patients
were included in the modiﬁed intent-to
treat (ITT) population. All randomly as-
signedpatientswhohadtakenatleastone
dose of study drug and had some post-
baseline data for the primary efﬁcacy pa-
rameter (2-h peak C-peptide) were
included in this population. The efﬁcacy
evaluable population included patients in
the ITT population who received at least
13 doses and did not have any major pro-
tocol deviations. The safety population
was deﬁned as all randomly assigned pa-
tients who received at least one dose of
study drug. All hypotheses testing was
two-sided and performed at the 5% sig-
niﬁcance level.
RESULTS— Of 188 patients who
were randomly assigned, 168 completed
the study (Fig. 1). The 20 patients who
dropped out of the study included 12
who withdrew consent, 3 who had an ad-
verse event, 2 who became pregnant, and
Figure 1—Study participation and randomization.
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Thefourtreatmentgroupsweresimilarin
terms of age, duration of disease, ethnic-
ity, and baseline C-peptide concentra-
tions (Table 1).
Safety parameters
Adverse events reported by 10% of pa-
tients were upper respiratory tract infec-
tion, nasopharyngitis, headache,
pharyngitis, inﬂuenza, nausea, rhinitis,
and vomiting. There was no clear pattern
ofrelationshipbetweendose,occurrence,
and frequency of adverse events. The fre-
quencies of adverse events in the NBI-
6024 treatment groups and the placebo
group were comparable. There was no
clinically signiﬁcant change in laboratory
or vital sign parameters. Overall, 39
(20.7%) patients were reported as experi-
encing at least one serious adverse event;
none of the serious adverse events was
considered to be drug-related.
Efﬁcacy parameters
The mean peak C-peptide value at month
24 and the change in the mean values
from baseline to month 24 were compa-
rable in the NBI-6024 treatment groups
and the placebo group in the ITT as well
as the efﬁcacy evaluable population (ITT
population mean peak C-peptide at 24
months: 0.1 mg, 0.39 pmol/ml; 0.5 mg,
0.39 pmol/ml; 1 mg, 0.33 pmol/ml; and
placebo, 0.39 pmol/ml; P  0.4, 0.3, and
0.6) (Fig. 2). Similarly, the mean AUCs of
Table 1—Patient demographics and history of diabetes by treatment group
Treatment group
Placebo
0.1 mg
NBI-6024
0.5 mg
NBI-6024
1.0 mg
NBI-6024
n 50 48 43 47
Age (years) 17.9  6.3 17.4  6.4 17.9  6.4 18.7  7.1
Sex
Male 31 26 30 31
Female 19 22 13 16
Peak C-peptide baseline (pmol/ml) 1.36  0.63 1.35  0.63 1.41  0.63 1.42  0.61
A1C baseline (%) 7.9  1.6 7.8  1.6 8.1  2.0 8.1  2.0
Daily insulin dose (IU) 31.3  19.4 33.1  15.8 30.5  11.9 32.1  14.9
Time since symptoms (months) 2.1  1.1 2.1  1.4 2.1  1.1 2.3  1.9
Time since diagnosis (months) 1.2  0.5 1.2  0.7 1.2  0.7 1.2  0.8
Data are means  SD or n.
Figure2—MeanfastingC-peptidelevels(forallsubjects[A])andmeanpeakC-peptidelevels(allsubjects[B],adolescents[C],andadults[D])after
mixed-mealstimulationinthefourtreatmentgroups.NosigniﬁcantdifferenceinC-peptidelevelswasobservedamongtreatmentgroups.Thedecline
in C-peptide secretion from baseline to 24 months was similar between adolescent patients and adults.
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theNBI-6024treatmentgroupsandinthe
placebo group were comparable (Table
2).Theaveragedailyinsulindosesneeded
at 24 months were 47.8  20.4, 57.2 
36.5, and 51.6  21.8 IU in the 0.1, 0.5,
and1mgNBI-6024treatmentgroups,re-
spectively, and 47.3  17.6 IU in the pla-
cebo group (P  0.9, 0.05, and 0.2) (Fig.
3). The A1C values at month 24 were
slightly higher in the NBI-6024 treatment
groups compared with that the placebo
group (0.1 mg, 8.1  2.1; 0.5 mg, 8.8 
3.0; 1 mg, 8.6  2.6; and placebo, 8.0 
2.1; P  0.7, 0.01, and 0.1) (Fig. 3). The
percentages of patients who reached an
A1C 7% at 24 months were 34, 32, 35,
and 29% in the NBI-6024 treatment
groups and the placebo group, respec-
tively (P  0.6, 0.9, and 0.6).
When the analysis was stratiﬁed by
age, no signiﬁcant difference was found
for peak C-peptide at month 24 or for the
decline in peak C-peptide from baseline
to24monthsbetweenadolescentpatients
and adults (Fig. 2). Furthermore, there
was no effect of sex or ethnicity.
Hypoglycemic events
Most hypoglycemic events were deemed to
beminorevents.Apairwisetreatmentcom-
parison showed no statistically signiﬁcant
difference between NBI-6024 treatment
groups compared with placebo in the
monthly rate of hypoglycemic events
(monthly rate: 0.1 mg, 1.9  2.0; 0.5 mg,
1.7  1.5; 1 mg, 1.9  1.6; and placebo
1.8  2.4; P  0.6, 0.3, and 0.4). Approx-
imately 9% of patients experienced a major
hypoglycemiceventduringthisstudy;these
patients were evenly distributed across
treatment groups.
Immune function parameters
Insulin antibodies increased in concentra-
tion from the baseline visit to month 1 and
remained stable thereafter in all groups. No
differencesinantibodiestoinsulin,GAD65,
and IA-2 were observed between treatment
and placebo groups at all study visits (sup-
plementaryFigureS1,availableinanonline
appendix at http://care.diabetesjournals.
org/cgi/content/full/dc09-0449/DC1). No
differenceswereobservedforCD4andCD8
peripheral blood T-cell numbers between
treatmentandplacebogroups(supplemen-
tary Figure S2).
CONCLUSIONS— For the ﬁrst
time, an APL was used for treatment of
autoimmune diabetes in a trial that in-
cluded 188 patients with recent-onset
disease. The APL NBI-6024, at the doses
studied,waswelltolerated.Therewereno
signiﬁcantsafetyissues,andmostadverse
events were considered mild or moderate
andunrelatedornotlikelytoberelatedto
thestudydrug.Thefrequencyofinjection
site reactions, a surrogate marker of im-
munoreactivity, was comparable among
placebo and active treatment groups.
Treatment with NBI-6024 at the doses
studied,however,providednoprotection
against the decline of -cell function after
diabetes onset, as measured by fasting or
stimulated C-peptide. Moreover, NBI-
6024 did not cause signiﬁcant changes in
insulin requirement, metabolic control,
hypoglycemic and hyperglycemic events,
autoantibodyconcentrations,orCD4and
CD8 T-cell numbers.
The NBI-6024 clinical trial was an in-
tensively monitored intervention study
that collected data on C-peptide, glucose,
and A1C every 3 months for 24 months
with central measurement of these vari-
ables. It provided a detailed natural his-
toryof-cellfunctionafterdiabetesonset
in unprecedented numbers of well char-
acterized and selected adolescents and
adults with recent-onset type 1 diabetes.
One limitation of the current trial is that
no T-cell response data were obtained to
verify an immunological effect at the
dosesgiven.However,thestudyincluded
three doses over a 10-fold range, which
had previously been shown to cause T-
cell unresponsiveness (7,8). The lack of
responsemayreﬂectafundamentaldefect
in the proposed mechanism of action or
inadequacy of exposure (dose), fre-
quency, or timing of the investigational
drug.
With respect to the natural history of
-cellfunction,thestudysuggestsalinear
continuousdeclineof-cellfunctionover
Table 2—AUC0–120 min C-peptide by treatment group
Treatment group
Placebo
0.1 mg
NBI-6024
0.5 mg
NBI-6024
1.0 mg
NBI-6024
Baseline 47 48 43 44
134  63 131  62 135  57 134  59
Month 24 42 46 37 40
57  71 53  56 44  55 50  45
P 0.5 0.6 0.9
Data are n or means  SD (pmol  min/ml).
Figure 3—Mean A1C values (A) and mean daily insulin requirement (B) in the four treatment groups.
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rate of decline was similar between ado-
lescentsandadultswithslopeestimatesof
0.034 and 0.031, respectively, for
peak C-peptide values. All three parame-
ters of -cell function examined (fasting
C-peptide, peak C-peptide, and AUC of
C-peptide response) in the mixed-meal
testshowedsimilardeclineswithanover-
all loss of 30% by 12 months of fol-
low-up and 60% by 24 months of follow-
up. These data are likely to be useful as
reference for other trials and for future
trial planning. For comparison, there was
a 50–60% decline in fasting and stimu-
lated C-peptide concentrations within 21
months in the recently reported GAD-
alum vaccination trial in patients aged
10–18 years (9).
In summary, this study failed to dem-
onstrate efﬁcacy of APL treatment in pa-
tients at the stage of overt disease. The
continuous decline of -cell function af-
ter onset, however, provides important
data for design and validation of future
clinical trials in patients with type 1 dia-
betes and conﬁrms the need for novel
treatment strategies (10) to reduce this
progressive -cell loss.
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APPENDIX— Members of the NBI-
6024 Study Group are the following:
South Africa: L. Distiller, A. Philotheou, R.
Moore, L.I. Robertson, J. Wing, G. Ellis,
B.D. Kramer, F.A. Mahomed, B.I. Joffe, F.
Bonnici,P.J.Wormald,S.Brown,A.Mur-
phy,N.Gurtunca,L.Hofmann,M.-T.van
der Merwe, S. Goldburg, and H. Well-
mann; U.K.: S. Greene and V. Franklin;
Czech Republic: J. Vavrinec, J. Venhacova,
Z. Sumnik, S. Kolouskova, O. Cinek, K.
Stechova,andP.Venhacova;Spain:R.Go-
mis, P. Martul, J.P. Lo ´pez-Siguero, D.
Acosta-Delgado, I. Conget, E. Aguilera,
J.A. Vazquez Garcia, L. Castan ˜o, F.
Vazquez San Miguel, I. Rica, V. Martín,
M
aS. Ruiz de Adana Navas, A. del Pino de
la Fuente, M.J. Garcia Arias, M.A. Mangas
Cruz, and R. Guerrero; Finland: I. Sipila ¨,
T. Saukkonen, P.J. Miettinen, and T.
Otonkoski; Germany: A.-G. Ziegler,
T. Danne, M. Fu ¨chtenbusch, M. Walter,
T. Kaupper, C. Bittner, W. von Schutz, A.
Krautzig, A. Hackenberg, and N. Datz;
Canada: A. Belanger, P. Perron, D. Pac-
aud, M. Lawson, J. Palardy, N. Kandalaft,
R. Duma, M.F. Langlois, K. Khoury, J.P.
Baillargeon, S. Lawrence, and A. Hadjiy-
annakis; and France: P.-F. Bougne `res, M.
Nicolino, M.C. Andre, J.C. Carel, P.P.
Boileau, M. Franc ¸ois, N. Bendelac, F.
Texier, P. Bretones, and C.-L. Gay.
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